产品
编 号：F377856
分子式：C31H20O10
分子量：552.48
分子式：C31H20O10
分子量：552.48
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 521-32-4
产品详情
生物活性：
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity.
体内研究：
Bilobetin (腹腔注射，12 mg/kg/天，4 或 14 天) 通过 PKA 介导的 PPARα 磷酸化，改善高脂饮食大鼠的高脂血症、脂毒性和胰岛素抵抗。Bilobetin (腹腔注射，50 mg/kg，持续 7 天) 可诱导大鼠肾损伤，并促进 AQP-2 转运至大鼠质膜上。Bilobetin (6 和 12 mg/kg，腹腔注射，每天一次， 10 天) 对顺铂 (Cisplatin (HY-17394)) (7 mg/kg，腹腔注射，第三天单剂量) 诱导的大鼠睾丸毒性具有保护作用。Animal Model:rats fed a high-fat diet
Dosage:12 mg/kg/day
Administration:i.p., 4 or 14 days after mice were fed a HFD for 8 weeks.
Result:Increased glucose infusion rate (GIR, P < 0.05) and reduced EGP (P < 0.05) in basal and clamp states.Reduced total TG (P < 0.01) and VLDL-TG (P < 0.01).Enhances hepatic Intralipid-TG uptake.Reduced the total amount of lipid level in the liver and muscle.Promoted the phosphorylation of PPARα and the translocation of PPARα from the cytoplasm to the nucleus in rats liver.
体外研究：
Bilobetin (0-40 μM，24/48/72 小时) 抑制 Huh7 和 HepG2 细胞的增殖。Bilobetin (0-20 μM，24 和 48 小时) 可诱导 Huh7 和 HepG2 细胞凋亡并增加亚 G1 细胞数量。Bilobetin (0-20 μM，24 小时) 会诱导 Huh7 和 HepG2 细胞中 ROS 积累和 DNA 损伤。Bilobetin (1-2 μM, 1 days) 抑制皮脂腺细胞中 AKT 的磷酸化。
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity.
体内研究：
Bilobetin (腹腔注射，12 mg/kg/天，4 或 14 天) 通过 PKA 介导的 PPARα 磷酸化，改善高脂饮食大鼠的高脂血症、脂毒性和胰岛素抵抗。Bilobetin (腹腔注射，50 mg/kg，持续 7 天) 可诱导大鼠肾损伤，并促进 AQP-2 转运至大鼠质膜上。Bilobetin (6 和 12 mg/kg，腹腔注射，每天一次， 10 天) 对顺铂 (Cisplatin (HY-17394)) (7 mg/kg，腹腔注射，第三天单剂量) 诱导的大鼠睾丸毒性具有保护作用。Animal Model:rats fed a high-fat diet
Dosage:12 mg/kg/day
Administration:i.p., 4 or 14 days after mice were fed a HFD for 8 weeks.
Result:Increased glucose infusion rate (GIR, P < 0.05) and reduced EGP (P < 0.05) in basal and clamp states.Reduced total TG (P < 0.01) and VLDL-TG (P < 0.01).Enhances hepatic Intralipid-TG uptake.Reduced the total amount of lipid level in the liver and muscle.Promoted the phosphorylation of PPARα and the translocation of PPARα from the cytoplasm to the nucleus in rats liver.
体外研究：
Bilobetin (0-40 μM，24/48/72 小时) 抑制 Huh7 和 HepG2 细胞的增殖。Bilobetin (0-20 μM，24 和 48 小时) 可诱导 Huh7 和 HepG2 细胞凋亡并增加亚 G1 细胞数量。Bilobetin (0-20 μM，24 小时) 会诱导 Huh7 和 HepG2 细胞中 ROS 积累和 DNA 损伤。Bilobetin (1-2 μM, 1 days) 抑制皮脂腺细胞中 AKT 的磷酸化。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备